NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD
0.23
+0 (+0.52%)
The current stock price of ONCO is 0.23 USD. In the past month the price decreased by -64.82%. In the past year, price increased by 27.99%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Onconetix Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. Onconetix, Inc. is a commercial stage biotechnology company. The company is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO US
Employees: 12
Company Website: https://onconetix.gcs-web.com/
Investor Relations: https://ir.bwbioinc.com/
Phone: 15136204101
The current stock price of ONCO is 0.23 USD. The price increased by 0.52% in the last trading session.
The exchange symbol of ONCONETIX INC is ONCO and it is listed on the Nasdaq exchange.
ONCO stock is listed on the Nasdaq exchange.
ONCONETIX INC (ONCO) has a market capitalization of 3.35M USD. This makes ONCO a Nano Cap stock.
ONCONETIX INC (ONCO) currently has 12 employees.
ONCONETIX INC (ONCO) has a support level at 0.23. Check the full technical report for a detailed analysis of ONCO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ONCO does not pay a dividend.
ONCONETIX INC (ONCO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-95.63).
The outstanding short interest for ONCONETIX INC (ONCO) is 2.06% of its float. Check the ownership tab for more information on the ONCO short interest.
Over the last trailing twelve months ONCO reported a non-GAAP Earnings per Share(EPS) of -95.63. The EPS decreased by -8438.24% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -83.34% | ||
ROE | -152.17% | ||
Debt/Equity | 0.29 |
ChartMill assigns a Buy % Consensus number of 43% to ONCO. The Buy consensus is the average rating of analysts ratings from 6 analysts.